Granules India's US arm launches generic Methergine tablets in US market

Published On 2018-06-02 04:45 GMT   |   Update On 2018-06-02 04:45 GMT

New Delhi: Granules India Ltd said its US subsidiary has launched the generic version of Methergine (Methylergonovine Maleate) tablets, in partnership with West-Ward Pharmaceuticals Corp, a wholly-owned subsidiary of Hikma Pharmaceuticals PLC.


Methylergonovine is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum haemorrhage. A press release issued by Granules said this is the first product that the company has commercialized from its R&D and manufacturing facility in Virginia.


"We are happy to have collaborated with Hikma. Apart from the fact that Hikma has a proven history of being a responsible player in the market, we look at this launch as the inception towards building a strategic relationship."


"The launch of generic Methergine tablets plays into our strategy of identifying patient needs and catering to them with economical alternatives," Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc, said.




Brian Hoffmann, President of West-Ward, said, "We are very pleased to be entering into a partnership with Granules Pharmaceuticals, Inc., adding this important oxytocic agent to our product portfolio in the US." "This partnership demonstrates our focus on improving patients access to high-quality, affordable medicines," he said.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News